Cargando…

Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma

Aim. Sal-like protein 4 (SALL4), is reexpressed in tissues of a subgroup of HCC associated with poor prognosis. Reports of SALL4 serological levels linked to HCC patients are meager and unclear in the prognosis of this malignancy. Methods. Immunohistochemistry and optical microscopy protocols were u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Su-xia, Wang, Jun-lan, Guo, Xi-jing, He, Chen-chen, Ying, Xia, Ma, Jin-lu, Zhang, Yuan-yuan, Zhao, Qian, Zhu, Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2014
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4016881/ https://www.ncbi.nlm.nih.gov/pubmed/24860834 http://dx.doi.org/10.1155/2014/262385

Ejemplares similares

Serum SALL4 as a predictive biomarker for the prognosis of patients with hepatocellular carcinoma who underwent nonsurgical treatment
por: Chen, Zhixian, et al.
Publicado: (2022)

SALL4 Expression in Hepatocellular Carcinomas Is Associated with EpCAM-Positivity and a Poor Prognosis
por: Park, Hyunjin, et al.
Publicado: (2015)

Elevated Preoperative Serum CA19-9 Levels in Patients with Hepatocellular Carcinoma Is Associated with Poor Prognosis after Resection
por: Chen, Yu-Ling, et al.
Publicado: (2013)

Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer
por: Misawa, Kiyoshi, et al.
Publicado: (2017)

SALL4 correlates with proliferation, metastasis, and poor prognosis in prostate cancer by affecting MAPK pathway
por: Zhou, Jie, et al.
Publicado: (2023)

Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer
por: Han, Su-xia, et al.
Publicado: (2015)

Both the serum AFP test and AFP/GPC3/SALL4 immunohistochemistry are beneficial for predicting the prognosis of gastric adenocarcinoma
por: Wang, Bingzhi, et al.
Publicado: (2021)

High levels of serum glypican‐1 indicate poor prognosis in pancreatic ductal adenocarcinoma
por: Zhou, Cong‐ya, et al.
Publicado: (2018)

Clinicopathologic characteristics of SALL4-immunopositive hepatocellular carcinoma
por: Shibahara, Junji, et al.
Publicado: (2014)

Screening of significant biomarkers with poor prognosis in hepatocellular carcinoma via bioinformatics analysis
por: Sun, Quanquan, et al.
Publicado: (2020)

SEPT2 crotonylation promotes metastasis and recurrence in hepatocellular carcinoma and is associated with poor survival
por: Zhang, Xin-yue, et al.
Publicado: (2023)

Autoantibodies against glucose-regulated protein 78 as serological biomarkers in metastatic and recurrent hepatocellular carcinoma
por: Ying, Xia, et al.
Publicado: (2017)

Positive expression of Midkine predicts early recurrence and poor prognosis of initially resectable combined hepatocellular cholangiocarcinoma
por: Ma, Ming-Chun, et al.
Publicado: (2018)

MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis
por: Huang, Xiao-Ying, et al.
Publicado: (2013)

Epigenetic modification of SALL1 as a novel biomarker for the prognosis of early stage head and neck cancer
por: Misawa, Kiyoshi, et al.
Publicado: (2018)

Overexpressed RING Finger 44 Correlates with Poor Prognosis in Hepatocellular Carcinoma
por: Liu, Yue, et al.
Publicado: (2022)

Increased expression of urotensin II is associated with poor prognosis in hepatocellular carcinoma
por: Liu, Dian-Gang, et al.
Publicado: (2016)

Cortactin is a sensitive biomarker relative to the poor prognosis of human hepatocellular carcinoma
por: Zhao, Gang, et al.
Publicado: (2013)

Decreased TPD52 expression is associated with poor prognosis in primary hepatocellular carcinoma
por: Wang, Ying, et al.
Publicado: (2015)

Clinical study of standard residual liver volume and transient elastography in predicting poor prognosis of patients after hemihepatectomy
por: Yue, Zhi-Qiang, et al.
Publicado: (2023)

MDFI is a novel biomarker for poor prognosis in LUAD
por: Chen, Pengyu, et al.
Publicado: (2022)

Long non-coding RNA CASC7 is a promising serum biomarker for hepatocellular carcinoma
por: Liao, Ling, et al.
Publicado: (2023)

Elevated serum visfatin levels are associated with poor prognosis of hepatocellular carcinoma
por: Sun, Yifan, et al.
Publicado: (2017)

MicroRNA-98 acts as a tumor suppressor in hepatocellular carcinoma via targeting SALL4
por: Zhou, Wuyuan, et al.
Publicado: (2016)

Universidad La Salle.

Les salles propres
por: Whyte, William, et al.
Publicado: (2001)

Elevated Preoperative Serum Gamma-glutamyltranspeptidase Predicts Poor Prognosis for Hepatocellular Carcinoma after Liver Transplantation
por: Fu, Shun-Jun, et al.
Publicado: (2016)

Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma
por: Miyoshi, A, et al.
Publicado: (2005)

SKA1 overexpression is associated with poor prognosis in hepatocellular carcinoma
por: Chen, Yibing, et al.
Publicado: (2018)

FABP4 suppresses proliferation and invasion of hepatocellular carcinoma cells and predicts a poor prognosis for hepatocellular carcinoma
por: Zhong, Cheng‐Qian, et al.
Publicado: (2018)

Association between tricuspid annular systolic velocity and poor short-term prognosis in patients with acute decompensated heart failure
por: Zhao, Kai, et al.
Publicado: (2022)

Serum HER2 as a predictive biomarker for tissue HER2 status and prognosis in patients with gastric cancer
por: Shi, Hong-Zhi, et al.
Publicado: (2017)

Proteinase-activated receptor 2 promotes tumor cell proliferation and metastasis by inducing epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma
por: Sun, Liang, et al.
Publicado: (2018)

hsa-mir-183 is frequently methylated and related to poor survival in human hepatocellular carcinoma
por: Anwar, Sumadi Lukman, et al.
Publicado: (2017)

High USP22 expression indicates poor prognosis in hepatocellular carcinoma
por: Tang, Bo, et al.
Publicado: (2015)

Serum Amyloid A is a biomarker of severe Coronavirus Disease and poor prognosis
por: Li, Huan, et al.
Publicado: (2020)

Pretreatment Liver Injury Predicts Poor Prognosis of DLBCL Patients
por: Shi, Qing, et al.
Publicado: (2017)

Decreased CRHBP expression is predictive of poor prognosis in patients with hepatocellular carcinoma
por: Xia, Hai-Bing, et al.
Publicado: (2018)

Six-long non-coding RNA signature predicts recurrence-free survival in hepatocellular carcinoma
por: Gu, Jing-Xian, et al.
Publicado: (2019)

Identification of recurrence-related serum microRNAs in hepatocellular carcinoma following hepatectomy
por: Wang, Liming, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_60j76lmf3mg6m2v3nbnrb7hjp2